(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 10.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 149.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.5%.
Veracyte's revenue in 2025 is $445,764,000.On average, 4 Wall Street analysts forecast VCYT's revenue for 2025 to be $38,242,667,045, with the lowest VCYT revenue forecast at $38,005,870,827, and the highest VCYT revenue forecast at $38,401,830,269. On average, 4 Wall Street analysts forecast VCYT's revenue for 2026 to be $42,057,829,800, with the lowest VCYT revenue forecast at $41,349,701,546, and the highest VCYT revenue forecast at $43,107,589,989.
In 2027, VCYT is forecast to generate $46,994,150,155 in revenue, with the lowest revenue forecast at $46,653,843,281 and the highest revenue forecast at $47,334,534,974.